Eli Lilly (LLY) Q1 2024 Earnings
LLY·Reported April 30, 2024·Before market open
Eli Lilly reported Q1 2024 revenue of $8.8B, missed analyst consensus of $8.9B by $167.8M. Diluted EPS came in at $2.58, beat the $2.46 consensus by $0.12. Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology.
Revenue
$8.8Bmissed by $167.8M
Consensus: $8.9BDiluted EPS
$2.58beat by $0.12
Consensus: $2.46
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Eli Lilly's Q1 2024 earnings report.
Eli Lilly (LLY) reported Q1 2024 earnings on April 30, 2024 before market open.
Eli Lilly reported revenue of $8.8B and diluted EPS of $2.58 for Q1 2024.
Revenue missed the consensus estimate of $8.9B by $167.8M. EPS beat the consensus estimate of $2.46 by $0.12.
You can read the 10-Q periodic report (0000059478-24-000118) directly on SEC EDGAR. The filing index links above go to sec.gov.